Recent news on Intron

Approvals: Herceptin, Reyataz, and Peg-Intron  -  May 21, 2007
Medscape (subscription)On April 5, the Chinese State Food and Drug Administration approved a new indication for peginterferon alfa-2b injection (Peg-Intron, Schering-Plough

Data Suggest that PEGASYS® May be an Option in Hepatitis C ...  -  May 21, 2007
WebWire (press release),Roche today announced results of a small study demonstrating that all patients who discontinued treatment with Peg-Intron® (peginterferon alfa-2b) and

Data Suggest that Pegasys May be an Option in Hepatitis C Patients ...  -  May 21, 2007
PharmaLive.com (press release),Overall, 88 percent of the total study population (100 percent of Peg-Intron non-tolerators and 81 percent of Peg-Intron non-responders) were able to

Multiferon(R) Shows Potent Activity in Preventing the Progression ...  -  May 8, 2007
PR Newswire (press release),We observed dramatically different outcomes when comparing Multiferon(R) against Intron(R) A in human melanoma cell lines in vitro, with Multiferon(R)

Multiferon(R) Shows Potent Activity in Preventing the Progression ...  -  May 9, 2007
PipelineReview.com (press release),Three human melanoma cell lines were grown at a range of different cell concentrations in the presence of graded doses of either Multiferon(R) or Intron(R)

Schering-Plough Announces Hepatitis C Data Presentations At ...  -  May 19, 2007
Medical News Today (press release),The incidence of severe adverse events in the PEGINTRON/REBETOL combination therapy trial was 23 percent in the INTRON A/REBETOL group and 31-34 percent in

New Disease and Therapy Review on Melanoma Features Chapters on ...  -  May 15, 2007
PharmaLive.com (press release),Dosing and treatment cost information is provided for the three approved melanoma treatments (Intron-A, Proleukin, and DTIC-Dome).

Pharmaceutical drugmakers slammed for marketing practices  -  May 11, 2007
Blogging Stocks...to the government about drug prices and illegally promoted the drugs Temodar and Intron A for the treatment of cancers for which they were not approved.

Biotechs and the generic drug market  -  May 10, 2007
Ars Technica,Drugs such as Epogen and Intron A are derived from cultured cells and then purified. This approach to developing drugs has been quite successful for

A Novel Mutation of Gene CBFA1/RUNX2 in Cleidocranial Dysplasia  -  May 23, 2007
Annals of Clinical & Laboratory Science (subscription),...the patient’s CBFA1/RUNX2 gene were identical to those obtained in controls, except for the one spanning the exon 7 and intron/exon boundary regions.

HIV and Hepatitis Therapies Continue to Drive Revenues in ...  -  May 23, 2007
PR Web (press release),...the launch of Pegasys, which it has bundled with its own ribavarin (Copegsys), while Schering-Plough markets its PEG Intron with its own ribavarin.

MIGENIX to Present Celgosivir Phase II Hepatitis C Results at ...  -  May 18, 2007
CNW Telbec (Communiqués de presse),...celgosivir has shown excellent in vitro synergy with various interferons in the clinic or in development including Pegasys, PEG-Intron, Infergen,

NY Times To Data-Mine Its Visitors  -  May 10, 2007
SlashdotRe:Obligatory?? by Intron (Score:2) Thursday May 10, @11:11AM. Re:Obligatory?? by Himring (Score:1) Thursday May 10, @10:34AM. Re:Obligatory?? by orclevegam

Companies marketing drugs for 'off-label' use  -  May 10, 2007
Miami Herald,...it lied to the government about drug prices and illegally promoted Temodar and Intron A for the treatment of certain cancers without approval.

Zacks Bull and Bear of the Day Highlights: Bayer AG, Enzon ...  -  May 10, 2007
Business Wire (press release),Further, another major source of revenue, Royalty, declined by 5% in the first quarter of 2007 due to anticipated decline in PEG-INTRON sales in Japan

1 From the Division of Endocrinology, Children's Hospital Boston ...  -  May 8, 2007
Am J Clin Nutr (subscription),A microsatellite within intron 3 of this transcription factor occurs with increased frequency in individuals with type 2 diabetes, which corresponds to an

Mutations in the Aryl Hydrocarbon Receptor Interacting Protein ...  -  May 4, 2007
Journal of Clinical Endocrinology and Metabolism,Design: The study design was the analysis of DNA from peripheral blood lymphocytes and analysis of exons 1–6 and paraexonic intron sequences of AIP.

Enzon Reports First Quarter 2007 Results  -  May 2, 2007
American Digital Networks (press release),US The majority of royalties is comprised of royalty revenue the Company receives on sales of PEG-INTRON, which remained relatively stable this quarter.

Justice Department Promises Stronger Copyright Punishments  -  May 14, 2007
Slashdot...by Intron (870560) on Monday May 14, @06:17PM (#19122299). I think there's nothing wrong with getting tough on illegally using IP as long as it is extended

Schering-Plough Sued in NJ for Marketing Drugs for Off-Label Uses  -  Apr 23, 2007
Law.com (subscription),The drugs at the center of the litigation are Intron A and Temador. Intron A, approved to treat hepatitis, has been prescribed for such off-label uses as

Vertex Vibrates Hepatitis Drug Sector  -  Apr 23, 2007
TheStreet.com...(Both Pegasys and Peg-Intron required weekly injections.) Follow-up data from a phase II study presented at the meeting showed that albufereon is just as

Vertex's Billion Dollar Drug?  -  Apr 18, 2007
Motley FoolComparing the Prove-1 study results to pivotal studies that helped lead to the approval of Pegasys and Peg-Intron shows the promise that telaprevir therapy

PEGINTRON(TM) Approved In China For Treating Chronic Hepatitis B  -  Apr 8, 2007
Medical News Today (press release),Schering-Plough has been working together with Chinese healthcare professionals and patients for nearly 15 years on hepatitis B education for INTRON(R) A,

Medical Edge: Benefits of hepatitis C drugs outweigh side effects  -  Apr 14, 2007
Bryan College Station Eagle,Interferon (brand name: Peg-Intron or Pegasys) is a protein that stimulates the immune system to attack invaders such as hepatitis C virus.

Confirmation That a Specific Haplotype of the Dopamine Transporter ...  -  Apr 2, 2007
Am J Psychiatry (subscription)Overall we find global evidence for association with the 3'UTR VNTR (p=0.019), the intron 8 VNTR (p=0.013), and the haplotype of the two markers (p=0.020).

Schering-Plough Addresses Major Milestones and Challenges in ...  -  Apr 11, 2007
PharmaLive.com (press release),The incidence of severe adverse events in the PEGINTRON/REBETOL combination therapy trial was 23 percent in the INTRON A/REBETOL group and 31-34 percent in

India's Successful Commercial Satellite Launch  -  Apr 24, 2007
Slashdot...by Intron (870560) on Tuesday April 24, @02:48PM (#18859295). New Delhi: Hello, please spell your name and give me your complete customer ID.

USPTO New Accelerated Review Process  -  Mar 28, 2007
SlashdotIntron writes "Perhaps you have been lying awake worrying that your software patent on bubble sort might spend too much time being "examined" or "peer

Enzon's PEG-SN38 Shows Anti-Tumor Activity in Resistant ...  -  Apr 18, 2007
PipelineReview.com (press release),...two of which Enzon markets, Adagen(R) and Oncaspar(R), and three for which Enzon receives royalties, PEG-INTRON(R), Pegasys(R), and Macugen(R).

News For Your Web Site  -  Apr 18, 2007
dBusinessNews Newark (press release),...two of which Enzon markets, Adagen® and Oncaspar®, and three for which Enzon receives royalties, PEG-INTRON®, Pegasys®, and Macugen®.

Enzon’s PEG-SN38 Shows Anti-Tumor Activity in Resistant ...  -  Apr 17, 2007
Business Wire (press release),...two of which Enzon markets, Adagen ® and Oncaspar ® , and three for which Enzon receives royalties, PEG-INTRON ® , Pegasys ® , and Macugen ® .

ViroPharma Announces Presentation of Additional HCV-796 Data at ...  -  Apr 14, 2007
PipelineReview.com (press release),Subsequent cohorts were comprised of subjects who received peg-IFN (PEG-Intron; 1.5 ug/kg/dose) on days -1 and 7 in combination with either placebo or

Study of Kir6.2/KCNJ11 gene in a sudden cardiac death pedigree.  -  Apr 14, 2007
HeartZine,The complete coding region and the intron-exon boundaries of KCNJ11 were amplified from genomic DNA using polymerase chain reaction (PCR).

New Clinical Study Results Indicate Higher Early Virologic ...  -  Apr 13, 2007
Drug Newswire (press release),...celgosivir has shown excellent in vitro synergy with various interferons in the clinic or in development including Pegasys, PEG-Intron, Infergen,

Biotech In Review: Bidding War Erupts For Biosite  -  Apr 7, 2007
Seeking Alpha,...hepatitis B. In China, Schering-Plough has been marketing Pegintron for hepatitis C since 2004, and it has offered Intron for hepatitis B since 1993.

Fresh from the Pipeline: Telbivudine  -  Apr 5, 2007
Nature.com (subscription),A recombinant form of interferon-- 2b (Intron A; Schering–Plough) became the first FDA-approved drug for treating HBV in 1992. It has the advantages of a

Confirmation That a Specific Haplotype of the Dopamine Transporter ...  -  Apr 2, 2007
Am J Psychiatry (subscription)...specific alleles of two variable-number tandem repeat polymorphisms within the 3' untranslated region and intron 8 of the dopamine transporter gene.

Singapore growing biopharma strength  -  Apr 2, 2007
DrugResearcher.com,The Singaporean sites manufacture Schering's hepatitis C treatment Peg-Intron (peginterferon alpha-2b) and Remicade (infliximab) for Crohn's disease and

Enzon Enrolls First Patient in Phase 1 Study of Its HIF-1 Alpha ...  -  Mar 29, 2007
PipelineReview.com (press release),In addition, Enzon also receives royalties on sales of PEG-INTRON(R), marketed by Schering-Plough Corporation, and Macugen(R), marketed by OSI

Metabolic Research, Inc. Appoints Dr. Robert Shorr as Chairman of ...  -  Mar 29, 2007
Genetic Engineering News (press release),Previously, he has served as Vice President Science and Technology at Enzon Inc., where he worked with Schering Plough to develop PEG INTRON A. Dr Shorr was

Enzon Enrolls First Patient in Phase 1 Study of Its HIF-1 Alpha ...  -  Mar 29, 2007
Business Wire (press release),In addition, Enzon also receives royalties on sales of PEG-INTRON®, marketed by Schering-Plough Corporation, and Macugen®, marketed by OSI Pharmaceuticals

Schering-Plough Reports Financial Results for First Quarter of 2007  -  Apr 19, 2007
PR Newswire (press release),160 28% TEMODAR 196 163 20% AVELOX 115 80 43% CLARITIN RX 112 101 11% INTEGRILIN 84 80 6% REBETOL 71 78 (8%) CAELYX 62 51 21% INTRON A 60 60 - SUBUTEX

Daylight Savings Time Puts Kid in Jail for 12 Days  -  Apr 17, 2007
Slashdot...by Intron (870560) on Tuesday April 17, @10:13AM (#18766835). I've eaten in the Hempstead cafeteria. They definitely have WMDs.

Medical Edge -- Hepatitis C treatment an ordeal worth enduring  -  Mar 12, 2007
Post-Bulletin,Interferon (brand name: Peg-Intron or Pegasys) is a protein that stimulates the immune system to attack invaders such as HCV. Although ribavirin doesn't

New Hampshire : Pharmaceutical Manufacturer Schering-Plough Pays ...  -  Feb 27, 2007
All American Patriots (press release),...and that it paid improper inducements to promote the prescribing of Intron-A, a bladder cancer treatment, and Peg-Intron and Rebetron, which are used to

DMP1-targeted Cre Expression in Odontoblasts and Osteocytes  -  Mar 23, 2007
Journal of Dental Research (subscription),Dmp1 promoter-4-kb 1st intron would be able to target Cre cDNA in these cells for expression/deletion of other genes in odontoblasts and osteocytes.

The vitamin D receptor and its ligand 1a,25-dihydroxyvitamin D 3 ...  -  Mar 22, 2007
Journal of EndocrinologyWe report the full sequence of the nuclear vitamin D receptor (sVDR0) and two alternatively spliced variants resulting from intron retention (sVDR1 and

New investor-backed clinics seek profits on demand for cancer care  -  Mar 21, 2007
Kyiv Post,Production of generic copies of top world drugs, such as Intron A, Roferon, Actimune, Enbrel, as well as the company’s own developed medicines,

Store Says DRM Causes 3 of 4 Support Calls  -  Mar 20, 2007
Slashdot...by Intron (870560) on Tuesday March 20, @02:14PM (#18418201). Anyway, I've returned a DVD because it wouldn't play on my computer. Not surprisingly, it was

Hazel is in the eye of the beholder; more on memory  -  Mar 19, 2007
USA TodayA three-SNP haplotype in the intron 1 of OCA2 explains most human eye color variation. American Journal of Human Genetics, 80: 241-252 (2007).

The Birth of Semiconductor 2.0  -  Mar 14, 2007
Slashdot...by Intron (870560) on Wednesday March 14, @06:27PM (#18355197). And what would cheap electronics printed right onto packaging do? This may be an advance,

Novel Mutations in the Parathyroid Hormone (PTH)/PTH-Related ...  -  Mar 6, 2007
Journal of Clinical Endocrinology and Metabolism,A homozygous nucleotide change (intron M4+27C>T) was demonstrated in one of the type II BOCD cases creating a novel splice site. In dermal fibroblasts of

Enzon to Present at Cowen 27th Annual Health Care Conference  -  Mar 6, 2007
Business Wire (press release),In addition, Enzon also receives royalties on sales of PEG-INTRON ® , marketed by Schering-Plough Corporation, and Macugen ® , marketed by OSI

Index of Online Supplemental Material for  -  Feb 26, 2007
Journal of Cell Biology (subscription)Figure S1 The presence of PGK-neo in the first intron of Rad51c leads to an insertion of its portion into Rad51c mRNA and results in a hypomorphic allele.

Understanding the Role of Sigma-1 Receptors in Psychotic Depression  -  Mar 15, 2007
Psychiatric Times,...(1998), Exon-intron structure, analysis of promoter region, and chromosomal localization of the human type 1 sigma receptor gene. J Neurochem 70(2):443-451.

Molecular Biology Techniques for Identifying Dermatophytes and ...  -  Mar 16, 2007
Journal of the American Podiatric Medical Association (subscription)OKEKE CN, TSUBOI R, KAWAI M, ET AL: Isolation of an intron-containing partial sequence of the gene encoding dermatophyte actin (ACT) and detection of a

Introns constrain change  -  Feb 6, 2007
Ars Technica,With the sequencing of a number of intron-filled genomes, researchers were in a position to ask that question, and an Open Access publication answers it:

Evolutionary influences on proteins  -  Feb 6, 2007
PressZoom (press release),Further, they also saw that smaller exons in which more of the nucleotides are close to an intron–exon boundary evolve more slowly.

Evolutionary Influences On Proteins  -  Feb 8, 2007
Medical News Today (press release),Splice-enhancer domains (exon sequences near the intron-exon boundary) help to ensure that this happens correctly. As they fall within the protein's exon,

Biolex Therapeutics Announces Initiation of Locteron(TM) Phase 2 ...  -  Jan 30, 2007
PR Newswire (press release),Investors: Dale Sander, Chief Financial Officer, 858-663-6993, dsander@biolex.com PEG-INTRON(R) is a registered trademark of Schering-Plough Corporation.

Biolex Therapeutics Announces Initiation Of Locteron(TM) Phase 2 ...  -  Jan 31, 2007
Medical News Today (press release),...less severe and of shorter duration than in the subjects receiving PEG-INTRON(R), the currently marketed interferon that served as the control.

Louisiana Settles with Schering-Plough  -  Feb 10, 2007
All American Patriots (press release),...drugs PEG-Intron and Rebetron, and bladder cancer medication Intron-A. Resulting losses to state Medicaid Programs were in excess of $80 million which,

Bruning Announces $1.8 Million Medicaid Fraud Settlement  -  Feb 9, 2007
Southwest Nebraska News,Finally, Schering allegedly paid kickbacks to doctors to induce them to prescribe hepatitis drugs PEG-Intron and Rebetron and bladder cancer medication

AG says Vermont received $725000 drug settlement  -  Feb 5, 2007
Legal News Line,...and K-Dur, and for partaking in illegal business practices with the drugs Temodar and Intron A. Schering-Plough was alleged to have offered kickbacks to

Schering-Plough Q4 profit up  -  Jan 29, 2007
Pharmaceutical Business ReviewSchering-Plough's leading prescription products like Remicade were up 32%, Nasonex up 28%, Peg-Intron up 11%, Temodar up 20%, and Clarinex/Aerius was up 12%

Enzon Reports 2006 Financial Results and Accomplishments  -  Feb 13, 2007
Genetic Engineering News (press release),In 2006, PEG-INTRON sales continued to grow as a result of the launch in Japan. However, as anticipated, Schering-Plough reported a decline in PEG-INTRON

Schering-Plough Reports Financial Results for 2006 Fourth Quarter ...  -  Jan 29, 2007
PR Newswire (press release),Sales of the company's PEG-INTRON hepatitis C product declined 3 percent to $208 million in the 2006 fourth quarter primarily due to the decline in sales in

Human Proteins Evolving Slowly Thanks To Multi-Tasking Genes  -  Feb 7, 2007
Medical News Today (press release),So, as well as spelling out which amino acids are needed to produce a specific protein, the part of the exon immediately next to the intron contains

Maryland : Maryland Attorney General Gansler Announces $1 Million ...  -  Feb 7, 2007
All American Patriots (press release),The settlement also resolves allegations that Schering made illegal payments to physicians to induce them to use its cancer drugs Temodar and Intron A for

An Intronic Growth Hormone Receptor Mutation Causing Activation of ...  -  Feb 6, 2007
Journal of Clinical Endocrinology and Metabolism,We previously described four mildly affected GHI patients with an intronic mutation in the GHR gene (A -1 G -1 substitution in intron 6), resulting in the

Vermont : Schering-Plough Pays $435 Million For Improper Marketing ...  -  Feb 6, 2007
All American Patriots (press release),The illegal marketing concerns the drugs Temodar, used in the treatment of brain tumors and metastases, and Intron A, used in the treatment of superficial

Brain Glucose Supply and the Syndrome of Infantile Neuroglycopenia  -  Feb 12, 2007
Archives of NeurologyAppropriate polymerase chain reaction primers were designed to yield DNA fragments spanning the entire GLUT1 coding region and intron-exon boundaries in

Enzon Announces Consolidation of Its Manufacturing Operations in ...  -  Feb 4, 2007
dBusinessNews Newark (press release),In addition, Enzon also receives royalties on sales of PEG-INTRON®, marketed by Schering-Plough Corporation, and MACUGEN®, marketed by OSI Pharmaceuticals

Enzon Announces Consolidation of Its Manufacturing Operations in ...  -  Feb 2, 2007
Business Wire (press release),In addition, Enzon also receives royalties on sales of PEG-INTRON ® , marketed by Schering-Plough Corporation, and MACUGEN ® , marketed by OSI

Enzon Announces Consolidation of Its Manufacturing Operations in ...  -  Feb 2, 2007
Genetic Engineering News (press release),In addition, Enzon also receives royalties on sales of PEG-INTRON(R), marketed by Schering-Plough Corporation, and MACUGEN(R), marketed by OSI

Earnings at Schering-Plough Climbed 75% in 4th Quarter  -  Jan 29, 2007
New York Times,The company said sales of its Peg-Intron hepatitis C product declined 3 percent, to $208 million, mainly on lower sales in Japan, as the number of new

Schering-Plough posts 75 percent rise in 4th-quarter profit  -  Jan 29, 2007
San Diego Union Tribune,The company said sales of its Peg-Intron hepatitis C product declined 3 percent to $208 million mainly on lower sales in Japan, as the number of new

Schering-Plough 4Q Profit Up 75 Percent  -  Jan 29, 2007
CBS News,The company said sales of its Peg-Intron hepatitis C product declined 3 percent to $208 million primarily due to lower sales in Japan, as the number of new

Schering-Plough profit rises on cholesterol drugs  -  Jan 29, 2007
San Diego Union Tribune,But sales of Peg-Intron, an interferon drug used to treat hepatitis C, slipped 3 percent to $208 million, hurt by declining demand in Japan.

Schering-Plough 4Q Profit Up 75 Percent  -  Jan 29, 2007
Forbes,The company said sales of its Peg-Intron hepatitis C product declined 3 percent to $208 million primarily due to lower sales in Japan, as a result of the

Schering-Plough profit boosted by Remicade  -  Jan 29, 2007
MarketWatchHowever, sales of the company's Peg-Intron hepatitis C product declined 3% to $208 million in the fourth quarter, primarily due a decline in sales in Japan.

Schering boosted by anti-cholestorol joint venture  -  Jan 29, 2007
MSNBCBut sales of Peg-Intron, the company's anti-hepatitis C drug, declined 3 per cent to $208m, as fewer patients started using the drug in Japan.

Schering-Plough Fourth Quarter Earnings Call  -  Jan 30, 2007
123Jump.com,Sales of the company''s PEG-INTRON hepatitis C product declined 3% to $208 million in the 2006 fourth quarter. This was primarily due to the decline in

Schering-Plough's turnaround is moving on apace  -  Jan 30, 2007
Pharma Times (subscription),Brain cancer treatment Temodar enjoyed a sales rise of 18% to $189 million, but Peg-Intron (peginterferon alfa) fell 3% to $208 million, hampered by a

Nasonex Unclogs Schering-Plough Profit  -  Jan 29, 2007
Smartmoney.comSales of the company's Peg-Intron hepatitis C product declined 3% to $208 million in the fourth quarter primarily due to the decline in sales in Japan,

Schering-Plough Q4 Profit Increases On Higher Prescription Drug ...  -  Jan 29, 2007
Trading Markets,Sales of the company's Peg-Intron hepatitis C product declined 3% to $208 million from $214 million in the year-ago quarter primarily due to the decline in

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional